MaaT Pharma is hoping a hearing with hematology experts will bolster its case as it seeks to overturn the European Medicines Agency’s rejection of its investigational microbiota-based therapy for acute graft-versus-host disease.
MaaT Pharma is hoping a hearing with hematology experts will bolster its case as it seeks to overturn the European Medicines Agency’s rejection of its investigational microbiota-based therapy for acute graft-versus-host disease.